140 likes | 156 Views
Hot Topics Clinical Medicine. ACHA Annual Meeting Boston, MA May 31, 2013. Important publication-LAST.
E N D
Hot TopicsClinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013
Hot Topics, Clinical Medicine Important publication-LAST • Consensus Guidelines (2012) The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology • Journal of Lower Genital Tract Disease, July 2012
Hot Topics, Clinical Medicine Basic intervals, normal pap history • Don’t start paps until 21 • 21-29 every 3 years, no co-testing • 30-64 every 3 years or every 5 years with co-testing • Over 65 no testing
Hot Topics, Clinical Medicine Unsatisfactory cytology on pap • With liquid-based technology, most reasons for unsatisfactory cytology are eliminated EXCEPT inadequate cells • Don’t use negative HPV co-testing as a reason not to repeat • Repeat test in 2-4 months
Hot Topics, Clinical Medicine Absent EC/TZ • Prior recommendation was early repeat • Under 30, manage as normal • Over 30, co-testor manage as normal • If negative co-test, routine repeat • If positive co-test, repeat cyto+co-test 1 year or • Genotype for 16, 18
Hot Topics, Clinical Medicine New concept 16, 18?
Hot Topics, Clinical Medicine • Test Name Result Flag(s) Reference Range Reported Date Footnote • CLINICAL INFORMATION: SEE NOTE • ALL NL PAPS • LMP: 4/6/2013 • PREV. PAP: N/A • PREV. BX: N/A • SOURCE: Cervix • STATEMENT OF ADEQUACY: SEE NOTE • Satisfactory for evaluation. Endocervical/transformation zone component present. • INTERPRETATION/RESULT: SEE NOTE • Negative for intraepithelial lesion or malignancy. • INFECTION: SEE NOTE • Shift in vaginal flora suggestive of bacterial vaginosis. • COMMENT: SEE NOTE • This Pap test has been evaluated with computer assisted technology. • CYTOTECHNOLOGIST: SEE NOTE • CXP, CT(ASCP) • HPV DNA (HIGH RISK) DETECTED A (NOT DETECTED) • High-risk HPV types 16,18,31,33,35,39,45,51,52,56,58,59, or 68 may cause cervical cancer or itsprecursors.The analytical performance characteristics of thisassay, when used to test SurePath or vaginal specimens,have been determined by Quest Diagnostics.Methodology: Hybrid Capture with Signal Amplification.
Hot Topics, Clinical Medicine New concept